Pfizer Seeks Deals With Chinese Biotechs to Offset Lost Revenue
5 years ago 1 min read
Pfizer Inc. is on the hunt for partnerships with Chinese biotech firms developing novel drugs, as the American pharmaceutical giant regroups after Beijing’s aggressive price-cutting campaign eroded profit margins in its mainstay blockbusters.
More Stories
Record Korean Cases; Trader’s Guide to Rollout: Virus Update
California Hits Record; Trader’s Guide to Rollout: Virus Update
AstraZeneca to Buy Alexion for $39 Billion in Rare-Disease Push